No Data
No Data
Scinai Immunotherapeutics Shares Are Trading Higher After the Company Announced It Regained Compliance With the Nasdaq.
Scinai Regains Full Compliance With Nasdaq Listing Requirements
Scinai Immunotherapeutics Restructures Debt, Boosts Equity
Press Release: Scinai Announces Closing of Loan Restructuring Agreement With European Investment Bank Converting Approximately $29 Million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript Summary
Express News | Scinai Immunotherapeutics Enters $2M Investment Commitment Agreement With RK Stone Miami, Allowing For ADS Sales Through December 2024 At Company's Discretion
No Data